NEW YORK (Reuters) – Alexion Pharmaceuticals Inc (ALXN.O) posted a better than expected second-quarter profit on Thursday and raised its full-year forecast on strong sales of its expensive rare disease treatment Soliris.
Shares of Alexion – which have been roiled by a scandal...
https://goo.gl/EAx6fi
Thursday, 27 July 2017
Alexion posts higher second-quarter earnings on strong Soliris sales
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment